| EMA number | EMEA/H/C/002577 |
| ATC code | J05AX11 |
| Authorisation | 13 November 2013 |
| Withdrawn | 3 November 2016 |
| Revision | 4 |
Vitekta co-administered with a ritonavir-boosted protease inhibitor and with other antiretroviral agents, is indicated for the treatment of human-immunodeficiency-virus-1 (HIV-1) infection in adults who are infected with HIV-1 without known mutations associated with resistance to elvitegravir.